Research · Source update
ACHIEVE-3 compares Foundayo with oral semaglutide in diabetes
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly presented direct oral-treatment results in people with type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly presented direct oral-treatment results in people with type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results, dated 2026-06-08.
What did the source report?
The sponsor reported better mean HbA1c and weight outcomes for the tested Foundayo regimen than oral semaglutide 14 mg. Lilly reported that orforglipron 17.2 mg achieved better HbA1c and weight changes than oral semaglutide 14 mg in ACHIEVE-3.
How should the results be interpreted?
The comparison is between products and doses used for diabetes, not every weight-management tablet. The quoted relative difference in weight reduction is not the same as percentage points or a comparison against oral semaglutide doses used for obesity.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
A true head-to-head study is still dose- and population-specific. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
A true head-to-head study is still dose- and population-specific.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-06-08. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results ↗
Source event or update: 2026-06-08. Our interpretation is educational and does not replace medical or insurance advice.